Accelerated rejection of the second transplants of immunogenic tumor in mice under inhibition of indoleamine 2,3-dioxygenaseactivity by ethyl pyruvate

Experimental Oncology

Volumn 34, Issue 1, 2012, Pages 66-68

  Vasilyeva, E D ^a   Kaledin, V ^a   Nicolin, V P ^a   Popova, N A ^a   Kirilyuk, I A ^b   Grigor'ev, I A ^b  

^a INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^b N N VOROZHTSOV NOVOSIBIRSK INSTITUTE OF ORGANIC CHEMISTRY   (Russian Federation)

Author keywords

Ethyl pyruvate; H 29 hepatocarcinoma; Indoleamine 2,3 dioxygenase; Tumor regression

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; PYRUVIC ACID ETHYL ESTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CANCER GRAFT; CANCER IMMUNIZATION; CONTROLLED STUDY; DRUG EFFECT; GRAFT REJECTION; IMMUNITY; IMMUNOGENIC TUMOR; INOCULATION; MOUSE; NONHUMAN; SURVIVAL; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENZYME INHIBITORS; GRAFT REJECTION; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MALE; MICE; MICE, INBRED C3H; NEOPLASMS; PYRUVATES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862492676     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogenic fetal rejection by triptophan catabolism. Science 1998; 281: 1191-3. (Pubitemid 28406294)
2. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by triptophan catabolism. Cell Death Differ 2002; 9: 1069-77.
3. Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1363-72. (Pubitemid 29227522)
4. Liu X, Newton RC, Friedman SM, Scherle PA. Indoleamine 2<3-dioxygenase, an emerging target for anti-cancer therapy. Current Cancer Drug Targets 2009; 9: 938-52.
5. Munn DH, Sharma MD, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114: 280-90. (Pubitemid 39071633)
6. Yoshida N, Ino K, Ishida Y, et al. Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Cloin Cancer Res 2008; 14: 7251-9.
7. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on triptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9: 1269-74. (Pubitemid 37279849)
8. Frieberg M, Jennings R, Alsarraj M, et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cellmediated rejection. Int J Cancer 2002; 101: 151-5. (Pubitemid 34970907)
9. Muller AJ, DuHadaway JB, Donover PS, et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11: 312-9. (Pubitemid 40460560)
10. Fink MP. Ethyl pyruvate: a novel anti-inflammatory agent. J Intern Med 2007; 261: 349-62. (Pubitemid 46474763)
11. Muller AJ, DuHadaway JB, Jaller D, et al. Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res 2010; 70: 1845-53.
12. Kaledin VI, Zhukova NA, Nikolin VP, et al. Hepatocarcinoma-29 - a metastasizing transplantable tumor provoking cachexia in host mice. Bul Exper Biol 2009; 148: 12: 664-9.
13. Vasilieva ED, Nikolin VP, Popova NA, et al. Inhiditor of activity of indoleamine 2,3-dioxygenase 1-methyl-Dtriptophan may stimulate the growth of immunogenic tumors. Bul Exper Biol 2010; 149: 559-61 (In Russian).
14. Kharchenko EP. Immunological privilege: pathological aspect. Immunology 2009; 4: 249-55 (In Russian).